2019

Experimental pharmacological research regarding some new quinazolin-4-ones derivatives

Cornel Chiriță

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania, chirita.cornel@gmail.com

Emil Ștefănescu

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania, emil_e_stefanescu@yahoo.com

Cristina E. Zbârcea

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania, cristinazbar@yahoo.com

Simona Negreș

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania, simona_negres@yahoo.com

Mihaela Bratu

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bucharest, Romania
Follow this and additional works at: <https://scholar.valpo.edu/jmms>

Part of the [Medicinal and Pharmaceutical Chemistry Commons](#), and the [Other Pharmacy and Pharmaceutical Sciences Commons](#)
See next page for additional authors

Recommended Citation

Chiriță, Cornel; Ștefănescu, Emil; Zbârcea, Cristina E.; Negreș, Simona; Bratu, Mihaela; Nuță, Diana C.; Limban, Carmen; Chiriță, Ileana C.; and Marineci, Cristina D. (2019) "Experimental pharmacological research regarding some new quinazolin-4-ones derivatives," *Journal of Mind and Medical Sciences*: Vol. 6 : Iss. 1 , Article 19.

DOI: 10.22543/7674.61.P121129

Available at: <https://scholar.valpo.edu/jmms/vol6/iss1/19>

This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Experimental pharmacological research regarding some new quinazolin-4-ones derivatives

Authors

Cornel Chiriță, Emil Ștefănescu, Cristina E. Zbârcea, Simona Negreș, Mihaela Bratu, Diana C. Nuță, Carmen Limban, Ileana C. Chiriță, and Cristina D. Marineci

Received for publication: May 30, 2018
Accepted: September 21, 2018

Research article

Experimental pharmacological research regarding some new quinazolin-4-ones derivatives

Cornel Chiriță¹, Emil Ștefănescu^{1*}, Cristina Elena Zbârcea¹, Simona Negreș¹, Mihaela Bratu², Diana Camelia Nuță², Carmen Limban², Ileana Cornelia Chiriță², Cristina Daniela Marineci¹

¹Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania

²Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bucharest, Romania

Abstract

A series of new compounds with quinazolin-4-one structure, synthesized by the Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of Medicine and Pharmacy “Carol Davila” Bucharest, was studied. Five of them were selected, conventionally named S1, S2, S3, S4, S5, and investigated in terms of their potential influence on the central nervous system (CNS). For this purpose, the antidepressant effect was determined using the forced swimming test; the anxiolytic/anxiogenic effect was determined using the suspended plus-shaped maze (Ugo Basile); the effect on the motor activity was determined using the Ugo Basile activity cage; and the potential analgesic effect was investigated using the hot plate test (Ugo Basile). Compounds S3 and S5 lowered the motor activity and showed an anxiolytic effect, while S1 and S2 proved to have antidepressant and analgesic effects.

A good correlation between antidepressant and analgesic effects was observed, consistent with the fact that analgesic drugs, by increasing norepinephrine and serotonin levels in the pain inhibiting descending pathways, can be used as co-analgesics in therapy.

Keywords : quinazolin-4-one derivatives, antidepressant, anxiolytic, analgesic, pharmacological research

Highlights

- ✓ S1 and S2 reduced the immobilization time in the forced swimming test by 25.98%, respectively 28.45%
- ✓ S3 and S5 have been shown to have relatively similar pharmacological profiles with respect to influence on HMA and VMA

To cite this article: Chiriță C, Ștefănescu E, Zbârcea CE, Negreș S, Bratu M, Nuță DC, Limban C, Chiriță IC, Marineci CD. Experimental pharmacological research regarding some new quinazolin-4-ones derivatives. *J Mind Med Sci.* 2019; 6(1): 121-129. DOI: 10.22543/7674.61.P121129

✉ *Corresponding author: Emil Ștefănescu, Carol Davila University of Medicine and Pharmacy, Department of Pharmacology and Clinical Pharmacy, Bucharest, Romania, 020956
E-mail: emil_e.stefanescu@yahoo.com

Introduction

Quinazoline derivatives have been studied in preclinical and clinical trials for many and various therapeutic purposes: antidepressant (1), anticonvulsant (2), analgesic (3), antineoplastic (4), antihypertensive (5), or tuberculostatic (6). Moreover, there are several approved drugs which belong to the carbamate ester derivatives class, many of them with cholinergic actions: physostigmine, neostigmine, or rivastigmine.

The new compound series, synthesized in the Pharmaceutical Chemistry Laboratory of the Faculty of Pharmacy within UMF “Carol Davila” Bucharest, brought together the 4(3H)-quinazolinone structure and carbamic ester group (7).

Table 1. Chemical structure of S₁- S₅ compounds

Compound
	R	Chemical name
S ₁		2-(2-Methyl-4-oxochinazolin-3(4H)-yl)-acetohydrazide
S ₂		1-[(2-Methyl-4-oxochinazolin-3(4H)-yl)-methyl]-3-(3-bromophenyl)-urea
S ₃		2-[2-(2-Methyl-4-oxochinazolin-3(4H)-yl)-acetyl]-hydrazino-N-(4-methoxyphenyl)-carbothioamide
S ₄		2-Methyl-3-[(5-phenyl-amino)-1,3,4-thiadiazole-2-yl)-methyl]-chinazolin-4(3H)-on
S ₅		2-Methyl-3-[(N-(3,5-dimethoxyphenyl)-carbonyl-oxy)-carbamoyl-methyl]-chinazolin-4(3H)-on

This synthesis resembles other similar processes that are part of the recent research directions of the Discipline of Pharmaceutical Chemistry, with the purpose of obtaining new chemical compounds with potential pharmacological actions (8-13).

In this paper, we present the results of the preclinical research performed on these five new compounds in order to assess the potential pharmacological actions on the central nervous system. We followed all the existing

protocols of the Laboratory of Pharmacology, the Faculty of Pharmacy, UMF “Carol Davila” Bucharest. We investigated the antidepressant effect using the forced swimming test, the anxiolytic/ anxiogenic effect using the suspended plus-shaped maze (Ugo Basile), the effect on the motor activity with the Ugo Basile activity cage, and the potential analgesic effect using the hot plate test, Ugo Basile (14).

Materials and Methods

A sample consisting of 94 white males, NMRI mice having reached maturity and weighing 25 ± 2.8 g, were supplied by the rodent farm of the University of Medicine and Pharmacy “Carol Davila”. Animals were quarantined for 3 days, and afterward, housed in ventilated cages with free access to food and water. Temperature and relative humidity were kept constant ($22-24^{\circ}\text{C}$, 45-60%).

All experimental procedures were carried out in accordance with the Directive 2010/63/UE of September 22nd, 2010, regarding the protection of animals used for experimental and other scientific purposes. All experimental procedures were approved by the Ethical Committee of the Faculty of Pharmacy Bucharest. The experiment was conducted in June 2014.

For the purpose of selecting the proper animals for the proposed pharmacological tests, 94 mice were subjected to the Ugo Basile activity cage test and divided into groups based on their horizontal motor activity, measured every 5 minutes. After exclusion of animals with extreme responses, 84 mice remained and were divided into 7 groups, each containing 12 individuals in such a manner that the average responses and the standard deviations were as similar as possible. Animals were then allowed one day for acclimation within their new groups. On the day of the experiment, each group was brought to the lab, one hour before the beginning of the experiment, to allow them to adapt to the new environment where they were kept without food.

The compounds were administered as shown below:

- Group I (control) – distilled water 0.1 ml/10g orally
- Group II (reference) – amitriptyline 10 mg/kg bw susp. 0.1% orally
- Group III – S₁ 100 mg/kg bw, susp. 1% orally
- Group IV – S₂ 100 mg/kg bw, susp. 1% orally
- Group V – S₃ 100 mg/kg bw, susp. 1% orally
- Group VI – S₄ 100 mg/kg bw, susp. 1% orally
- Group VII – S₅ 100 mg/kg bw, susp. 1% orally

One hour after treatment, the mice were subjected to the activity cage test to determine their motor activity and then to the forced swimming test, in order to determine the potential antidepressant effect of the new compounds.

One week after the first set of tests (considered enough time for the compounds to have been purged from the system), all groups received the same treatment again and were subjected first to the suspended cross-maze test in order to determine the levels of anxiety, and then to the hot plate test, in order to evaluate the potential analgesic effects of the researched compounds.

All tests were conducted in accordance with the following protocol: in the testing chamber, animals were kept in artificial light, without food. Each individual was administered the treatment with a 7-minute delay from the previous one (5 minutes for the test itself and 2 minutes to clean the device before testing the next animal) so that all could be tested after the same time interval from the moment of receiving the treatment.

The *determination of the motor activity* to assess the effect on the central nervous system by recording the horizontal and vertical movements of mice in the Activity Cage Ugo Basile was performed by placing a mouse in a corner of the device and monitoring its movements for 5 minutes.

The *determination of the immobility* time of mice in forced swimming test (FST) was accomplished by placing each mouse in a glass cylinder (25 cm height, 30 cm diameter) containing a 20 cm high column of water at a temperature of $22 \pm 1^\circ\text{C}$ and recording during a 4-minute interval after a prior 2-minute interval for adaptation (15).

The *determination of curiosity* used the suspended cross-shaped maze and involved placing the mouse in the center of the device and measuring the time spent in the open arms compared to the time spent in the enclosed arms during a 5-minute interval.

The *evaluation of pain sensitivity* was performed using the hot-plate test which consists of placing the mouse on a metal plate heated to a 53°C temperature and measuring the latency to the mouse's reaction of licking its forepaws or of trying to escalate the Plexiglas walls of the plate.

Statistical analysis

Statistical analysis used the software GraphPad Prism 5. Comparison between groups used the Student t test (for normal distribution) whereas comparison across multiple groups used ANOVA. When significant, the Bonferroni posttest adjustment was performed for posthoc comparisons. The normality of the response distribution in collectivity was tested with the D'Agostino & Pearson test.

Results and Discussions

Group forming

The 84 mice remaining after excluding 10 individuals with extreme responses were divided in 7 homogenous groups, each containing 12 individuals. Their baseline motor activity is shown below.

Table 1. The homogenous groups formed after the selection process

	Group 1		Group 2		Group 3		Group 4		Group 5		Group 6		Group 7	
	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA
M	621.8	101.6	621.1	110.4	623	95.83	616.5	104.8	623.5	105.8	623.5	103.3	622.9	105.5
SD	110.8	27.58	104.1	22.75	75.1	22.93	118.9	18.45	99.33	19.24	91.19	20.73	70.68	12.59

M = average; HMA = horizontal motor activity; VMA = vertical motor activity; SD = standard deviation

Figure 1. Normal distribution of the HMA results

Figure 2. Normal distribution of the VMA results

Motor activity determination

Figure 1. HMA – effect vs Control

All of the newly synthesized quinasolines reduced the motor activity. S5 had the most intense effect, inducing a 29.08% reduction in HMA and a 37.78% reduction in VMA compared to the control group, which were statistically significant.

Figure 2. VMA – effect vs Control

S3 also had an intense effect, but the reduction of the motor activity in this case was not statistically significant. Amitriptyline, which was used as the reference substance, did not influence significantly the motor activity after the acute administration.

Table 2. HMA and VMA results

	Control		Reference		S1		S2		S3		S4		S5	
	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA	HMA	VMA
M	509	61.4	490.6	55.4	504.7	52.1	470.5	54.3	407.2	44.2	447.4	49.3	357.3	38.2
SD	114.1	32.5	108.2	17.6	56.5	19.3	64.9	26.3	66	15.3	119.6	22.9	130.8	34.8
ND	DA	DA	DA	DA	DA	DA	DA	DA	DA	DA	DA	DA	DA	DA
Eff% vs Control	-	-	-3.61%	-9.77%	-0.84%	-15.15%	-7.56%	-11.56%	-20.00%	-28.01%	-12.1%	-19.71%	-29.8%	-37.78%
Anova/HMA	P= 0.004 (**)													
Bonferroni HMA	S5/Control: p<0.01; S5/Reference: p<0.01													
Anova/VMA	NS													

M = average; HMA = horizontal motor activity; VMA = vertical motor activity; SD = standard deviation; ND = normal distribution; NS = statistically not significant

Antidepressant effect evaluation

Table 3. Immobilization time results

	Control	Reference	S1	S2	S3	S4	S5
M	128.7	98.00	95.27	92.08	146.30	139.50	133.30
SD	41.94	22.40	22.33	21.45	25.74	24.64	26.04
ND	DA	DA	DA	DA	DA	DA	DA
% variation of the immobilization time vs Control		-23.85%	-25.98%	-28.45%	13.68%	8.39%	3.57%
Anova	P<0.0001 (***)						
Bonferroni Posttest	S2/Control: p<0.05						

The forced swimming test was performed after acute treatment, with this test giving positive results even after a single dose, in the case of classical antidepressant drugs.

Figure 3. FST - immobilization time + SD

As expected initially, Amitriptyline reduced the immobilization time by 23.85% compared to controls. The result however was not statistically significant, probably due to the large within-group variance.

The antidepressant effect of Amitriptyline is well documented in the scientific literature (7, 16). Among the tested compounds, the highest reduction in the

The average immobilization time for each group and the effect compared to the control group is shown in the following figure.

Figure 4. The evaluation of the antidepressant effect of the newly synthesized compounds

immobilization time was induced by S2, thus indicating that it has the most intense antidepressant effect (28.45%; $p < 0.05$ – ANOVA + Bonferroni posttest). Similarly, S1 reduced the immobilization time by 25.98%. The other three compounds proved to have no significant antidepressant effect after only one administration.

Behavior evaluation in the suspended cross-shaped maze

Table 4. Time spent in the open arms of the maze

	Control	Reference	S1	S2	S3	S4	S5
M	38.33	40.25	37.17	34.92	55.33	41.42	51.50
SD	19.89	19.14	14.94	11.15	28.45	25.07	27.82
ND	DA	DA	DA	DA	DA	DA	DA
Time variation (%) vs Control		5.01%	-3.03%	-8.9%	44.35%	8.06%	34.36%
Anova	NS						

M = average; SD = standard deviation; ND = normal distribution NS = statistically not significant

Table 5. Time spent in the enclosed arms of the maze

	Control	Reference	S1	S2	S3	S4	S5
M	261.7	259.8	262.8	265.1	244.7	258.6	248.5
SD	19.89	19.14	14.94	11.15	28.45	25.07	27.82
ND	DA	DA	DA	DA	DA	DA	DA
Time variation (%) vs Control		-0.73%	0.42%	1.3%	-6.5%	-1.18%	-5.04%
Anova	NS						

M = average; SD = standard deviation; ND = normal distribution NS = statistically not significant

Figure 5. Average time in the open arms +SD

Figure 6. Average time in the enclosed arms + SD

Figure 7. Time variation (%) in open arms

Figure 8. Time variation (%) in enclosed arms

In the suspended cross-maze test, neither of the tested compounds induced statistically significant changes. However, S3 resulted in a 44.35% increase in the time spent in the open arms, and S5 had a similar effect (34.36%). Acknowledging the fact that, under the influence of anxiolytic drugs, mice tend to spend more time in the open arms than the enclosed ones

further suggests that S3 and S5 might have such an effect. Another parameter that can give information regarding the anxiolytic potential of a new substance is the number of exits performed by mice outside the open arms. The mean, standard deviations, and comparison with the control group for this parameter are shown below.

Table 6. Number of exits outside the open arms							
	Control	Reference	S1	S2	S3	S4	S5
M	21	22.42	14.42	15.33	23.92	17.83	24.83
SD	3.27	5.12	7.47	5.66	7.31	5.65	6.04
ND	DA	DA	DA	DA	DA	DA	DA
Exit number variation (%) vs Control		6.76%	-31.33%	-27%	13.9%	-15.1%	18.24%
Anova	P<0.0001 (***)						
Bonferroni Posttest	S1/Reference: p<0.05						

M = average; SD = standard deviation; ND = normal distribution; *** = very high statistical significance

Figure 7. Average number of exits + SD

The results confirm that these 2 compounds (S3 and S5) have the highest anxiolytic potential, S3 having increased the

Figure 8. Number of exits variation (%) vs Control

number of exits by 13.9% compared to the control group, while S5 shows a similar and stronger pattern, 18.24%.

Analgesic effect evaluation

Table 7. Time until the first reaction to the heat stimulus (53°C)							
	Control	Reference	S1	S2	S3	S4	S5
M	4.34	4.80	7.77	6.89	5.58	6.67	4.85
SD	1.28	2.04	2.26	2.45	1.7	1.92	3.34
ND	DA	DA	DA	DA	DA	DA	DA
Time variation (%) vs Control before first reaction		10.60%	79.03%	58.76%	28.57%	53.69%	11.75%
Anova	P<0.0018 (**)						
Bonferroni Posttest	S1/Control: p<0.01; S1/Reference: p<0.05						

M = average; SD = standard deviation; ND = normal distribution; ** = high statistically significance

Figure 9. Average time of the first pain reaction

Figure 10. Analgesic effect vs Control

S1 has the most intense analgesic effect compared to the control group (79.03%, $p < 0.01$, ANOVA + Bonferroni) and also to the reference group (61.87%, $p < 0.05$, ANOVA + Bonferroni). S2 also delayed the first pain reaction by 58.76% compared to the control group, while S4 delayed by 53.69%. S3 and S5 had negligible analgesic effects (17, 18).

Amitriptyline used as a reference had a low analgesic effect after a single dose of 10 mg/kg bw. This result is consistent with the other reports (19, 20).

The scientific literature also mentions the use of tricyclic antidepressants as co-analgesics in the treatment of some forms of pain (21).

Conclusions

The five new quinasolines tested in this study induced various changes in the parameters investigated in the preclinical tests conducted.

S3 and S5 proved to have similar pharmacological profiles in that while S3 lowered HMA by 20% and VMA by 28.01% compared to the control group, S5 had the same effect on HMA (29.8%; $P < 0.01$ - ANOVA + Bonferroni) and to VMA, which was lowered by 37.78% compared to the control group.

The same 2 compounds showed the most intense anxiolytic potential by increasing the time spent in the open arms of the cross-maze (S3: 44.35%; S5: 34.36%) on one hand, and, on the other hand, the number of exits from the open arms (S3: 13.9%; S5: 18.24%). However, S3 and S5 had no antidepressant or analgesic effect.

S1 and S2 reduced the immobilization time in the forced swimming test by 25.98% and 28.45% respectively ($p < 0.05$; ANOVA + Bonferroni). The same 2 compounds also registered the most intense analgesic effects compared to the control group (S1: 79.03%, $p < 0.01$; S2: 58.76%). S1 had a significant analgesic effect also compared to amitriptyline (61.87%, $p < 0.05$; ANOVA + Bonferroni).

A good correlation between the antidepressant and the analgesic effects was observed, which is consistent with the fact that analgesic drugs, by increasing the norepinephrine and serotonin levels in the pain inhibiting descending pathways, can be used as co-analgesics in therapy.

From our analyses, we confirm that the tested compounds have high pharmacological potential worthy of further investigation.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and such approvals are acknowledged within the manuscript.

References

1. Kashaw SK, Kashaw V, Mishra P, Jain NK, Stables JP. Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea. *Eur J Med Chem.* 2009; 44(11): 4335-43. DOI: 10.1016/j.ejmech.2009.05.008
2. Paneerselvam P, Raj T, Ishar MPS, Singh B, Sharma V, Rather BA. Anticonvulsant activity of Schiff bases of 3-amino-6,8-dibromo-2-phenyl-quinazolin-4(3H)-ones. *Indian J Pharm Sci.* 2010; 72(3): 375-8. DOI: 10.4103/0250-474X.70488
3. Alagarsamy V, Murugesan S. Synthesis and pharmacological evaluation of some 3-(4-methoxyphenyl)-2-substitutedamino-quinazolin-4(3H)-ones as analgesic and anti-inflammatory agents. *Chem Pharm Bull.* 2007; 55(1): 76-80.
4. Selvam P, Murugesan N, Chandramohan M, Pannecouque C, De Clercq E. Synthesis, Antiviral and Cytotoxic Activities of 2-(2-Phenyl carboxylic acid)-3-Phenylquinazolin-4(3H)-one Derivatives. *Indian J Pharm Sci.* 2010; 72(6): 806-9.
5. Chaudhary M, Bhattachary S, Ahmad Y. Synthesis of some novel triazolo-quinazolinone derivatives and investigation of their antihypertensive agents. *Der Pharmacia Sinica.* 2012; 3(4): 479-87.
6. Kwnes J, Bazant J, Pour M, Waisser K, Slosarek M, Janota J. Quinazolines derivatives with antitubercular activity. *Il Farmaco.* 2000; 55(11-12): 725-9.
7. Bratu M, Nuță DC, Căproiu MT, Missir AV, Limban C, Chiriță IC, Morușciag L. New acylated derivatives of 2-methyl-4-oxo-quinazolin-3(4h)-yl-acetohydroxamic acid. *Farmacia* 2014; 62(4): 664-73.
8. Chiriță C, Cioroianu DM, Chiriță IC, Negreș S, Marian B, Zbârcea CE. Synthesis and pharmacological activity of new acyl-oximines derivatives. *Farmacia* 2016; 64(1): 61-6.

9. Cioroianu DM, Morușciag L, Căproiu MT, Limban C, Chiriță IC, Nuță DC. Synthesis and characterization of new acyl-oximines derivatives with potential pharmacological activity. *Farmacia* 2013; 61(3): 469-80.
10. Limban C, Missir AV, Nuță DC, Căproiu MT, Morușciag L, Chiriță C, Cupii A, Gurgu H. Advances in research of new 2-((4-ethylphenoxy) methyl)-N-(arylcarbamoithiyl)benzamides. *Farmacia* 2015; 63(3): 376-80.
11. Limban C, Missir AV, Nuță DC, Căproiu MT, Papacoea MT, Chiriță C. Synthesis of some new 2-((4-chlorophenoxy)methyl)-n-(arylcarbamoithiyl) benzamides as potential antifungal agents. *Farmacia* 2016; 64(5): 775-9.
12. Motofei IG. A bihormonal model of normal sexual stimulation; the etiology of premature ejaculation. *Med Hypotheses*. 2001; 57(1): 93-5.
13. Rotaru ID, Nuță DC, Chiriță IC, Căproiu MT, Limban C, Missir AV, Chiriță C. New synthesis in the n[4-[(phenylcarbamoil)amino]-phenyl]benzenesulfonamide derivatives series. note 1. *Farmacia* 2016; 64(6): 828-33.
14. Chiriță C, Ștefănescu E, Marineci CD, Negreș S, Nuță DC. Experimental pharmacological research regarding some newly synthesized benzamides on central nervous system functions. *J Mind Med Sci*. 2017; 4(2): 148-55.
15. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. *Arch Int Pharmacodyn Ther*. 1977; 229(2): 327-36.
16. Dableh LJ, Yashpal K, Rochford J, Henry JL. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. *Eur J Pharmacol*. 2005; 507(1):99-105.
17. Özdoğan ÜK, Lähdesmäki J, Mansikka H, Scheinin M. Loss of amitriptyline analgesia in $\alpha 2A$ -adrenoceptor deficient mice. *Eur J Pharmacol*. 2004; 485(1): 193-6.
18. Stefanescu DC, Ciucu AA, Rabinca AA, et al. An Integrative Medical Perspective on Novel Dopamine Detection Method. *Revista de chimie* 2018; 69(1): 277-281.
19. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. *Neuropharmacology*. 2005; 48(2): 252-63.
20. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? *Psychopharmacology* 1988; 94(2):147-60.
21. Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. *Physiological reviews* 2009; 89(2):707-58.